A clinical-stage biotech making vaccines with its XpressCF cell-free protein synthesis platform, which builds conjugate shots without the immune-dampening carrier proteins that limit conventional pneumococcal vaccines. Its lead candidates, VAX-31 and VAX-24, aim at pneumococcal disease in adults and children, and its pipeline also covers strep and shigellosis. The company gained control of its cell-free extract manufacturing through an agreement with Sutro Biopharma.
Select a row to see that insider’s individual transactions. † Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last year: -101.6K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.